苦参素胶囊联合拉米夫定治疗乙型肝炎早期肝硬化35例  

Oxymatrine Capsule combined with Lamivudine in the Treatment of Early Cirrhosis of Chronic Hepatitis B for 35 Cases

作　　者：金学洙[1] 

机构地区：[1]长春中医药大学附属医院肝脾胃病科,长春130021

出　　处：《中国中医药现代远程教育》2015年第23期58-59,共2页Chinese Medicine Modern Distance Education of China

摘　　要：目的分析苦参素联合拉米夫定治疗乙型肝炎早期肝硬化的临床效果。方法选取2013年1月—2014年6月收治的70例乙型肝炎早期肝硬化患者为研究对象,将其随机分为观察组与对照组,观察组给予苦参素联合拉米夫定治疗,对照组仅给予拉米夫定治疗,对比观察两组患者临床治疗效果。结果治疗后,观察组HBV-DNA转阴率、HBe Ag转阴率均高于对照组(P<0.05);治疗前,两组患者ALT、TBIL、ALB等肝功能指标与对照组比较,无显著差异(P>0.05);治疗后,观察组ALT、TBIL、ALB等肝功能指标优于对照组(P<0.05);且治疗前两组HA、LN、PC-Ⅲ等肝纤维化指标比较,无显著差异(P>0.05);治疗后,观察组HA、LN、PC-Ⅲ等肝纤维化指标优于对照组(P<0.05)。结论苦参素联合拉米夫定治疗乙型肝炎早期肝硬化的临床效果显著,值得推广。Objective To analyzethe clinical effect of oxymatrine combined with lamivudine in the treatment of early cirrhosis of chronic hepatitis B. Methods Selecting 70 cases of patients with early cirrhosis of chronic hepatitis B in our hospital from January 2013 to June2014 as research objects, they were randomly divided into observation group and control group. The observation group used oxymatrine combined with lamivudine. The control group received lamivudine. The clinical effect of the two groups was compared. Results After treatment, the HBV-DNA negative rate and the HBe Ag negative rate of the observation group were higher than those of the control group（ P 〈0.05）. Before treatment, the ALT, TBIL, ALB and other liver function of the two groups had no significant difference（ P〉 0.05）. After treatment, ALT, TBIL, ALB and other liver function of the observation group were better than those of the control group（ P〈0.05）. Before treatment, HA, LN, PC-Ⅲ and other liver fibrosis of the two groups had no significant difference（ P〉 0.05）. After treatment, HA, LN, PC-Ⅲand other liver fibrosis of the observation group were better than those of the control group（ P 〈0.05）. Conclusion The oxymatrine combined with lamivudine in the treatment of early cirrhosis of chronic hepatitis B has significant clinical effect, and is worthy of promotion.

关 键 词：苦参素胶囊 拉米夫定 乙型肝炎 早期肝硬化 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]